Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

136.73 +1.13 (+0.83%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
$39M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Charles River Laboratories International, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Charles River Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Charles River Laboratories International, Inc. (CRL) Investors of Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Why Charles River Stock Is Plunging Today
Via Benzinga
Charles River Dives As Monkey Investigation Hamstrings 2023 Outlook
The DOJ is investigating shipments of nonhuman primates from Cambodia. 
Via Investor's Business Daily
CRL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors With Losses In Excess of $100K to Inquire About Securities Class Action Investigation – CRL
From The Rosen Law Firm, P.A.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
This Favorable Sign Appears On Charles River's Chart
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Jim Cramer Says This Stock Is Undervalued: 'I Think That It's Coming Back'
On CNBC’s "Mad Money Lightning Round," Jim Cramer he wants to own Sherwin-Williams Co (NYSE: SHW). "Everything that they could possibly say negative about it is out there. 
Via Benzinga
Charles River Laboratories Acquires SAMDI Tech
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Charles River Laboratories International, Inc. (NYSE: CRL) is trading at 20 time 
Via Benzinga
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
What Does Charles River's Debt Look Like?
Over the past three months, shares of Charles River Inc. (NYSE:CRL) increased by 16.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.